« Back to Record
Citation APA

Spraggs, C. C., Parham, L. L., Briley, L. L., Warren, L., Williams, L. L., Fraser, D. D., Jiang, Z., Aziz, Z., Ahmed, S., Demetriou, G., Mehta, A. A., Jackson, N., Byrne, J., Andersson, M., Toi, M., Harris, L., Gralow, J., Zujewski, J. A., Crescenzo, R., Armour, A., Perez, E., & Piccart-Gebhart, M. (2018). Characterisation of the HLA-DRB107:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. Pharmacogenomics journal, 18(3), 480-486. doi:10.1038/tpj.2017.39


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/278653

Spraggs, C. C., Parham, L. L., Briley, L. L., Warren, L., Williams, L. L., Fraser, D. D., Jiang, Z., Aziz, Z., Ahmed, S., Demetriou, G., Mehta, A. A., Jackson, N., Byrne, J., Andersson, M., Toi, M., Harris, L., Gralow, J., Zujewski, J. A., Crescenzo, R., Armour, A., Perez, E., & Piccart-Gebhart, M. (2018). Characterisation of the HLA-DRB107:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. Pharmacogenomics journal, 18(3), 480-486. doi:10.1038/tpj.2017.39